Free Trial

Vaccine Results From Johnson & Johnson Carefully Watched

EQUITIES

One US earnings release that could garner some interest today could be Johnson & Johnson - they're due pre-market. Outside of their EPS and revenue headlines, markets will be looking for any efficacy results of their COVID-19 vaccine, and whether testing is showing an efficacy of 80% or more.

  • Bloomberg today citing an Evercore ISI survey, in which their results show investors expect a "sustained rotation into reopening stocks" if the JNJ results show a decent level of effectiveness.
  • The last two quarters, JNJ have reported at 1140GMT/0640ET, so that seems a good guide for timing of any release we may see from them today.
MNI London Bureau | +44 203-865-3809 | edward.hardy@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.